Lockheed Martin Investment Management CO Vertex Pharmaceuticals Inc Transaction History

Lockheed Martin Investment Management CO

$2.15 Billion
Q3 2024

A detailed history of Lockheed Martin Investment Management CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Lockheed Martin Investment Management CO holds 9,950 shares of VRTX stock, worth $4.09 Million. This represents 0.22% of its overall portfolio holdings.

Number of Shares

9,950

Holding current value

$4.09 Million

% of portfolio

0.22%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $4.58 Million - $5.03 Million	9,950 New	9,950 $4.63 Million
Q1 2021 May 12, 2021	SELL	$207.02 - $241.31 $5.03 Million - $5.87 Million	-24,320 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$207.01 - $276.09 $1.76 Million - $2.35 Million	8,500 Added 53.73%	24,320 $5.75 Million
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $4.04 Million - $4.8 Million	15,820 New	15,820 $4.3 Million
Q3 2019 Nov 14, 2019	SELL	$166.23 - $187.09 $5.64 Million - $6.35 Million	-33,950 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $3.12 Million - $3.61 Million	18,950 Added 126.33%	33,950 $6.23 Million
Q1 2019 May 10, 2019	BUY	$163.73 - $194.7 $2.46 Million - $2.92 Million	15,000 New	15,000 $2.76 Million
Q3 2018 Nov 13, 2018	SELL	$167.73 - $192.74 $687,693 - $790,234	-4,100 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$145.72 - $169.96 $174,864 - $203,952	-1,200 Reduced 22.64%	4,100 $697,000
Q1 2018 Apr 26, 2018	BUY	$151.6 - $177.13 $803,480 - $938,789	5,300 New	5,300 $0

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lockheed Martin Investment Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Lockheed Martin Investment Management CO with notifications on news.

Account

Lockheed Martin Investment Management CO Vertex Pharmaceuticals Inc Transaction History